My Account | Shopping Cart | Contact  
Trilink Biotech Logo

Oligonucleotides | mRNA & Long RNA | Nucleotides | CleanCap® | CleanTag® | CleanAmp® | Custom Chemistry | cGMP

OligoBuilder® | Nucleotides List | Stocked mRNA List | DNA Synthesis Reagents List | CleanAmp™ Products List

You are at: All > Nucleotides > Nucleotides by Structural Class > Base Modified Ribonucleoside Triphosphates

Pseudo-UTP, 5-Ribosyl Uracil


Extinction Coefficient: 7,546 Lmol-1cm-1 at 262 nm
Molecular Weight: 484.1 g/mol (free acid)
Molecular Formula: : C9H15N2O15P3 (free acid)
Salt Form: Lithium
Purity Specification: ≥97% by AX-HPLC

Shipped at 100 mM in H2O.
1 µmole: 10 µL
5 µmole: 50 µL
10 µmole: 100 µL

Purchase with 5-Methyl-CTP and ARCA, save 10%!
Certificate(s) of Analysis


Pseudouridine (5-ribosyluracil) was the first modified ribonucleoside discovered. It is the most abundant natural modified RNA base, and has been deemed the "fifth nucleoside" in RNA. It can be found in structural RNAs, such as transfer, ribosomal and small nuclear RNA. Pseudouridine has been found to enhance base stacking and translation.
Pseudouridine-5'-triphosphate (Pseudo-UTP) is used to impart desirable mRNA characteristics such as increased nuclease stability, increased translation or altered interaction of innate immune receptors with in vitro transcribed RNA. Pseudo-UTP, along with 5-methylcytidine-5'-triphosphate (5-methyl-CTP) has shown innate immune suppression in culture and in vivo while enhancing translation in recent publications.
For example, Warren et al. determined an efficient means of reprogramming multiple human cell types using modified mRNA that can express the four primary reprogramming proteins. These cells are referred to as induced pluripotency stem cells (iPSCs). Warren et al. found that enzymatically synthesized RNA substituted with Pseudo-UTP, 5-Methyl-CTP and ARCA effectively evaded the cell’s innate immune response, a crucial component in their success. Reduced toxicity due to substitution with Pseudo-UTP, 5-Methyl-CTP was critical since it allowed repeated transfection with in vitro transcribed mRNA over several weeks.

Kariko "We value TriLink, it is an excellent company indeed. The product is very good and the costumer service is very good too. Actually a nucleic acid chemist, my friend Dr. János Ludwig recommended me your company in the spring of 2004. That time I was looking for modified-nucleoside triphosphates to generate transcripts that would help to prove or disprove the hypothesis related to lack of immunogenicity of the heavily modified tRNAs. Anyway, he gave me a long list of companies that sell or custom synthesize modified NTP, but told me that start with TriLink, they are good. And now everybody I know who is making pseudoU RNA is getting it from you."

Katalin Karikó, PhD Adjunct Associate Professor of Neurosurgery
University of Pennsylvania

Email a Friend
Product Inquiry
Ready To Order?

Please select a size :
   1 µmole ($91.00)
   5 µmoles ($425.00)
   10 µmoles ($728.00)


Related Products :

Related Categories :

Wroblewska L, Kitada T, Endo K, Siciliano V, Stillo B, Saito H, Weiss R.Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery.Nat Biotechnol. 2015 Aug
Uchida S, Kataoka K, Itaka K.Screening of mRNA Chemical Modification to Maximize Protein Expression with Reduced Immunogenicity.Pharmaceutics. 2015 Jul 23
Pratico ED, Feger BJ, Watson MJ, Sullenger BA, Bowles DE, Milano CA, Nair SK.RNA-Mediated Reprogramming of Primary Adult Human Dermal Fibroblasts into c-kit+ Cardiac Progenitor Cells.Stem Cells Dev. 2015 Aug 13.
Abraham MK, Nolte A, Reus R, Behring A, Zengerle D,et al.In vitro Study of a Novel Stent Coating Using Modified CD39 Messenger RNA to Potentially Reduce Stent Angioplasty-Associated Complications.PLoS One. 2015 Sep
Poleganov MA, Eminli S, Beissert T, Herz S, Moon JI, et al. Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion.Hum Gene Ther. 2015 Oct 1
Baba M, Itaka K, Kondo K, Yamasoba T, Kataoka K. Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles.J Control Release. 2015 Jan 17;201C:41-48. doi: 10.1016/j.jconrel.2015.01.017
Andries O,Mc Cafferty S,et al.N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice.J Control Release. 2015 Sep 3
Hausburg F, Na S, Voronina N, Skorska A, Müller P, Steinhoff G, David R. Defining Optimized Properties of Modified mRNA to Enhance Virus- and DNA- Independent Protein Expression in Adult Stem Cells and Fibroblasts. Cell Physiol Biochem. 2015 Feb 12
Lee K, Yu P, Lingampalli N, Kim HJ, Tang R, Murthy N.Peptide-enhanced mRNA transfection in cultured mouse cardiac fibroblasts and direct reprogramming towards cardiomyocyte-like cells.Int J Nanomedicine. 2015 Mar 6
Michel T, Kankura A,Salinas Medina ML,Kurz J,Behring A,Avci-Adali M,Nolte A,et al.In Vitro Evaluation of a Novel mRNA-Based Therapeutic Strategy for the Treatment of Patients Suffering from Alpha-1-Antitrypsin Deficiency.Nucleic Acid Ther. 2015 Jun 30
Guo XR, et al. PDX-1 mRNA-induced reprogramming of mouse pancreas-derived mesenchymal stem cells into insulin-producing cells in vitro. Clin Exp Med. 2014 Oct 28.
Wang Xiao, et al. Reprogramming human umbilical cord mesenchymal stromal cells to islet-like cells with the use of in vitro–synthesized pancreatic-duodenal homebox 1 messenger RNA. Volume 16, Issue 11, November 2014, Pages 1519–1527
Wang Y, Su HH, Yang Y, Hu Y, Zhang L, Blancafort P, Huang L. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther. 2013 Feb;21(2):358-67.
Uchida S, Itaka K, Uchida H, Hayakawa K, Ogata T, Ishii T, Fukushima S, Osada K, Kataoka K. In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle. PLoS One. 2013;8(2):e56220.
Hernandez LI, Flenker KS, Hernandez FJ, Klingelhutz AJ, McNamara JO, Giangrande PH. Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers. Pharmaceuticals. 2013; 6(3):295-319.
Mandal PK, Rossi DJ. Reprogramming human fibroblasts to pluripotency using modified mRNA. Nat Protoc. 2013 Feb 21;8(3):568-82.
Pardi N, Muramatsu H, Weissman D, Karikó K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol Biol. 2013;969:29-42. doi: 10.1007/978-1-62703-260-5_2.
Karikó K, Muramatsu H, Keller JM, Weissman D. Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin. Mol Ther. 2012 Feb 14. doi: 10.1038/mt.2012.7.
Anderson BR, Karikó K, Weissman D. Nucleofection induces transient eIF2α phosphorylation by GCN2 and PERK. Gene Ther. 2012 Feb 2. doi: 10.1038/gt.2012.5.
Karikó K, Muramatsu H, Keller JM, Weissman D. Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin. Mol Ther. 2012 Feb 14. doi: 10.1038/mt.2012.7.
Warren L, Ni Y, Wang J, Guo X. Feeder-free derivation of human induced pluripotent stem cells with messenger RNA. Sci Rep. 2012;2:657.
Green NM, Moody KS, Debatis M, Marshak-Rothstein A. Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands. J Biol Chem. 2012 Sep 27. doi: 10.1074/jbc.M112.383000jbc.M112.383000.
Kariko K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein encoding mRNA. (2011) Nucleic Acids Research.
Anderson, B.R., Muramatsu, H., Jha, B.K., Silverman, R.H., Weissman, D., Kariko, K. Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L (2011) Nucleic Acids Research, EPub Aug
Anderson, B., Muramatsu, H., Nallagatla, S.R., Bevilacqua, P.C., Sansing, L.H., Weissman, D. & Kariko, K. Incorporation of pseudouridine into mRNA enhances translation by dimishing PKR activation (2010) Nucleic Acids Research, 38(17): 5884-5892.
Warren et al., Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA, Cell Stem Cell (2010), doi:10.1016/j.stem.2010.08.012.
Kariko K, Muramatsu H, Welsh F, et al. Incorporation of Pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. (2008) Molecular Therapy (16)11: 1833-1840.
Belliot G, Sosnovtcev SV, Chang KO, Babu V, Uche U, Arnold JJ, Cameron CE, Green KY. Norovirus proteinase-polymerase and polymerase are both active forms of RNA-dependent RNA polymerase. (2005) Journal of Virology, 79(4): 2393-2403.
Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modifiation and the Evolutionary Origin of RNA (2005). Immunity, 23(2), 165-175.
Charette M, Gray MW. Pseudouridine in RNA: what, where, how, and why. IUBMB Life. 2000 May;49(5):341-51.
Madore E, et. al. Effect of modified nucleotides on Escherichia coli tRNAGlu structure and on its aminoacylation by glutamyl-tRNA synthetase. Predominant and distinct roles of the mnm5 and s2 modifications of U34. Eur J Biochem. 1999 Dec;266(3):1128-35.
Goldberg IH, Rabinowitz M. Comparative utilization of pseudouridine triphosphate and uridine triphosphate by ribonucleic acid polymerase. (1963) J. Biol. Chem., 238(5): 1793-1800.



  Twitter Twitter Facebook Facebook Linked In Linked In RSS RSS Google RSS  
© 2019 TriLink BioTechnologies, LLC | All Rights Reserved